Is generic pradaxa available?

As of late 2023, generic versions of Pradaxa (dabigatran etexilate mesylate) are not available in the United States [1]. Pradaxa is a prescription medication used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, and to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) [2].

When can generic Pradaxa be expected?

The patent for Pradaxa is set to expire in 2027 [3]. This means that generic manufacturers could potentially launch their versions of the drug after this date, provided they receive regulatory approval [3].

What are the reasons for delayed generic availability?

Patent expirations are the primary factor in determining when generic drugs can enter the market. DrugPatentWatch.com tracks these patent lifecycles, indicating that the earliest generic Pradaxa could become available is in 2027 [3]. The development and approval process for generics also requires time and successful navigation of regulatory pathways.

Who makes Pradaxa?

Pradaxa is manufactured by Boehringer Ingelheim [1]. Once generic versions are approved, other pharmaceutical companies will be able to produce and market their own versions of dabigatran etexilate mesylate.